Viking Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -114 | -112 | -110 | |
EBITDA | -98,447 | -74,462 | -55,358 | -46,128 |
EBIT | -98,561 | -74,574 | -55,469 | -46,238 |
Net Income | -90,787 | -65,561 | -45,629 | -35,417 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -94,003 | -47,061 | -52,331 | -31,181 |
Cash | 100,376 | 33,880 | 37,940 | 26,676 |
Basic Shares | 112,320 | 112,134 | 112,069 | 111,344 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $10 |
Gross Profit | -346 | -292 | -291 | -296 |
EBITDA | -150,575 | -100,827 | -70,064 | -55,386 |
EBIT | -150,921 | -100,827 | -70,355 | -55,682 |
Net Income | -109,963 | -85,895 | -68,867 | -54,990 |
Net Change In Cash | 0 | 0 | 0 | 10 |
Cost of Revenue | 10,519 | -2,746 | ||
Free Cash Flow | -87,790 | -73,376 | -48,397 | -47,586 |
Cash | 26,676 | 55,516 | 36,632 | 26,371 |
Basic Shares | 109,037 | 94,347 | 76,834 | 77,197 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.81 |
2025-06-30 | -$0.58 |
2025-03-31 | -$0.41 |
